File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Gut microbiota composition is associated with SARS-CoV- 2 vaccine immunogenicity and adverse events

TitleGut microbiota composition is associated with SARS-CoV- 2 vaccine immunogenicity and adverse events
Authors
Issue Date2022
Citation
Gut, 2022, v. 71, n. 6, p. 1106-1116 How to Cite?
AbstractObjective: The gut microbiota plays a key role in modulating host immune response. We conducted a prospective, observational study to examine gut microbiota composition in association with immune responses and adverse events in adults who have received the inactivated vaccine (CoronaVac; Sinovac) or the mRNA vaccine (BNT162b2; BioNTech; Comirnaty). Design: We performed shotgun metagenomic sequencing in stool samples of 138 COVID-19 vaccinees (37 CoronaVac and 101 BNT162b2 vaccinees) collected at baseline and 1 month after second dose of vaccination. Immune markers were measured by SARS-CoV-2 surrogate virus neutralisation test and spike receptor-binding domain IgG ELISA. Results: We found a significantly lower immune response in recipients of CoronaVac than BNT162b2 vaccines (p<0.05). Bifidobacterium adolescentis was persistently higher in subjects with high neutralising antibodies to CoronaVac vaccine (p=0.023) and their baseline gut microbiome was enriched in pathways related to carbohydrate metabolism (linear discriminant analysis (LDA) scores >2 and p<0.05). Neutralising antibodies in BNT162b2 vaccinees showed a positive correlation with the total abundance of bacteria with flagella and fimbriae including Roseburia faecis (p=0.028). The abundance of Prevotella copri and two Megamonas species were enriched in individuals with fewer adverse events following either of the vaccines indicating that these bacteria may play an anti-inflammatory role in host immune response (LDA scores>3 and p<0.05). Conclusion: Our study has identified specific gut microbiota markers in association with improved immune response and reduced adverse events following COVID-19 vaccines. Microbiota-targeted interventions have the potential to complement effectiveness of COVID-19 vaccines.
Persistent Identifierhttp://hdl.handle.net/10722/341348
ISSN
2023 Impact Factor: 23.0
2023 SCImago Journal Rankings: 8.052
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNg, Siew C.-
dc.contributor.authorPeng, Ye-
dc.contributor.authorZhang, Lin-
dc.contributor.authorMok, Chris K.P.-
dc.contributor.authorZhao, Shilin-
dc.contributor.authorLi, Amy-
dc.contributor.authorChing, Jessica Y.L.-
dc.contributor.authorLiu, Yingzhi-
dc.contributor.authorYan, Shuai-
dc.contributor.authorChan, Dream L.S.-
dc.contributor.authorZhu, Jie-
dc.contributor.authorChen, Chunke-
dc.contributor.authorFung, Adrian C.H.-
dc.contributor.authorWong, Kenneth K.Y.-
dc.contributor.authorHui, David S.C.-
dc.contributor.authorChan, Francis K.L.-
dc.contributor.authorTun, Hein M.-
dc.date.accessioned2024-03-13T08:42:06Z-
dc.date.available2024-03-13T08:42:06Z-
dc.date.issued2022-
dc.identifier.citationGut, 2022, v. 71, n. 6, p. 1106-1116-
dc.identifier.issn0017-5749-
dc.identifier.urihttp://hdl.handle.net/10722/341348-
dc.description.abstractObjective: The gut microbiota plays a key role in modulating host immune response. We conducted a prospective, observational study to examine gut microbiota composition in association with immune responses and adverse events in adults who have received the inactivated vaccine (CoronaVac; Sinovac) or the mRNA vaccine (BNT162b2; BioNTech; Comirnaty). Design: We performed shotgun metagenomic sequencing in stool samples of 138 COVID-19 vaccinees (37 CoronaVac and 101 BNT162b2 vaccinees) collected at baseline and 1 month after second dose of vaccination. Immune markers were measured by SARS-CoV-2 surrogate virus neutralisation test and spike receptor-binding domain IgG ELISA. Results: We found a significantly lower immune response in recipients of CoronaVac than BNT162b2 vaccines (p<0.05). Bifidobacterium adolescentis was persistently higher in subjects with high neutralising antibodies to CoronaVac vaccine (p=0.023) and their baseline gut microbiome was enriched in pathways related to carbohydrate metabolism (linear discriminant analysis (LDA) scores >2 and p<0.05). Neutralising antibodies in BNT162b2 vaccinees showed a positive correlation with the total abundance of bacteria with flagella and fimbriae including Roseburia faecis (p=0.028). The abundance of Prevotella copri and two Megamonas species were enriched in individuals with fewer adverse events following either of the vaccines indicating that these bacteria may play an anti-inflammatory role in host immune response (LDA scores>3 and p<0.05). Conclusion: Our study has identified specific gut microbiota markers in association with improved immune response and reduced adverse events following COVID-19 vaccines. Microbiota-targeted interventions have the potential to complement effectiveness of COVID-19 vaccines.-
dc.languageeng-
dc.relation.ispartofGut-
dc.titleGut microbiota composition is associated with SARS-CoV- 2 vaccine immunogenicity and adverse events-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1136/gutjnl-2021-326563-
dc.identifier.pmid35140064-
dc.identifier.scopuseid_2-s2.0-85126224389-
dc.identifier.volume71-
dc.identifier.issue6-
dc.identifier.spage1106-
dc.identifier.epage1116-
dc.identifier.eissn1468-3288-
dc.identifier.isiWOS:000754021900001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats